Evidence map›Paper›PMID 38792621›Full record

ArticleLife (Basel, Switzerland)2024

Phage Biosensor for the Classification of Metastatic Urological Cancers from Urine.

Vilhelmiina Juusti, Antti Rannikko, Anu Laurila, Maria Sundvall, Pekka Hänninen, Janne Kulpakko

Abstract read
In one paragraph

Article in Life (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Vilhelmiina JuustiLaboratory of Biophysics and Medicity Research Laboratories, Institute of Biomedicine, Faculty of Medicine, University of Turku, Tykistökatu 6A, 20520 Turku, Finland.ORCID 0000-0002-9264-5417
Antti RannikkoDepartment of Urology, Helsinki University, Helsinki University Hospital, 00280 Helsinki, Finland.
Anu LaurilaDepartment of Oncology, Turku University Hospital, PL52, 20521 Turku, Finland.
Maria SundvallDepartment of Oncology, Turku University Hospital, PL52, 20521 Turku, Finland.ORCID 0000-0002-0494-2965
Pekka HänninenLaboratory of Biophysics and Medicity Research Laboratories, Institute of Biomedicine, Faculty of Medicine, University of Turku, Tykistökatu 6A, 20520 Turku, Finland.ORCID 0000-0001-5481-3275
Janne KulpakkoAqsens Health Ltd., Itäinen Pitkäkatu 4B, 20520 Turku, Finland.

Funding

Aqsens Health Ltd.
6 · The paper itself

Abstract

Most of the annual 10 million cancer-related deaths are caused by metastatic disease. Survival rates for cancer are strongly dependent on the type of cancer and its stage at detection. Early detection remains a challenge due to the lack of reliable biomarkers and cost-efficient screening methods. Phage biosensors can offer a solution for early detection using non-invasive liquid biopsies. Here, we report the first results of the bifunctional phage biosensor to detect metastatic urological cancers from urine. A dye-sensitized phage library was used to select metastasis-related phage binders. After selection rounds, the most promising phage candidate was used to classify metastatic cancer from controls. Additionally, we applied one chemical sensor (phenoxazine non-fluorescent dye) to classify cancer from urine. A statistical significance (

Indexed as

biosensorchemical sensorliquid biopsyliquid crystalmetastatic cancerphagephage biosensorurineurological cancer

Identifiers

PMID38792621
PMCPMC11122065

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.